Updates on Gardasil

Interesting excerpts from American Thinker article pasted below. These cause some pause. (Here is a link to an article by Steven W. Mosher and Joan Robinson of the Population Research Institute (PRI), commenting on the talk by Merck consultant Dr. Diane Harper, who helped develop both Gardasil and Cervarix.)

Dr. Harper has on several occasions criticized the rush to market of both HPV drugs. But her October 2 talk at the Fourth International Public Conference on Vaccination in Reston, Va., was framed as emphasizing the benefits of Gardasil. Nevertheless, according to PRI, her presentation openly stated that, 26 million vaccinations after its debut, Gardasil will have no effect on the rate of cervical cancer in the U.S. HPV, the infection that Gardasil can prevent, is rare, usually heals itself, and testing and treatment in the U.S. are very effective in keeping cervical cancer a rare event.
....

PRI's Joan Lewis adds: "To date, 15,037 girls have officially reported adverse side effects from Gardasil to the Vaccine Adverse Event Reporting System (VAERS). These adverse effects include Guilliane Barre, lupus, seizures, paralysis, blood clots, brain inflammation and many others. The CDC acknowledges that there have been 44 reported deaths."
....

Merck's Dr. Harper told CBS News that a girl is more likely to die from an adverse reaction to Gardasil than from cervical cancer. [my emphasis added]